

CAPLACIZUMAB

BRAND NAME	CABLIVI
DRUG CLASS	Nanobody (bivalent, humanised), antithrombotic
AVAILABILITY	Vial contains 10 mg of caplacizumab. Also contains sucrose, citric acid, sodium citrate dihydrate and polysorbate-80. Prefilled syringe contains 1 mL of water for injections. ¹
pH	No information
PREPARATION	Reconstitute the vial using the prefilled syringe and vial adaptor provided. Add the solvent slowly and mix gently to avoid foaming. With the syringe still attached, allow the vial to stand for 5 minutes at room temperature before drawing the dose back into the syringe. ¹ The solution is clear and colourless to slightly yellow. ¹
STABILITY	Vial: store at 2 to 8 °C. Stable for 2 months below 25 °C. Do not return to the fridge. ¹ Reconstituted solution: stable for 4 hours at 25 °C. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	The first dose must be given by IV injection. ¹ Inject into the abdomen. While undergoing daily plasma exchange treatment, inject the dose after plasma exchange. ¹ Suitable for self-administration after appropriate patient education. ¹
IV injection	Suitable for the first dose, inject the dose before plasma exchange. ¹
IV infusion	Not recommended
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Missed doses can be given within 12 hours. If more than 12 hours has elapsed wait for the next dose. ¹ Caplacizumab increases the risk of bleeding. Contact the pharmacist for advice about use with anticoagulants or antiplatelets or preceding surgery. ¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 28/04/2020.